In October 2017 we were able to treat a severely ill asthmatic patient in Calgary ICU with our experimental S1226 drug. Results were in the words of the lead...
CALGARY, AB – December 6, 2016. SolAeroMed Inc. is excited to report a brand new investment opportunity. Please click here to find out more information about our new investment announcement for...
CALGARY, Alberta, May 30, 2016 – SolAeroMed Inc. (“SolAeroMed”), a Calgary-based biotechnology company dedicated to developing novel drugs and devices to treat respiratory diseases, today announced positive Phase IIa proof-of-concept results...
